オートインジェクター市場 : 使用法 (再利用可能、使い捨て)、技術 (手動、自動)、治療法 (関節リウマチ、糖尿病、アナフィラキシー)、投与経路 (SC、IM)、容量 (<3ml、>3ml)、エンドユーザー (在宅医療、病院) – 2028年までの世界予測
Autoinjectors Market by Usage (Reusable, Disposable), Technology (Manual, Automatic), Therapy (Rheumatoid Arthritis, Diabetes, Anaphylaxis), Route of administration (SC, IM), Volume (<3ml, >3ml), End User (Home Care, Hospitals) – Global Forecast to 2028
The global autoinjector devices market is projected to reach USD 1.7 billion in 2028 from USD 0.9 billion in 2023, growing at a CAGR of 14.0%. Where as, the autoinjector finished formulations market is projected to reach USD 136.5 billion in 2028 from USD 59.6 billion in 2023, growing a CAGR of 18.0%. The key factors driving the growth of the autoinjectors market are the increasing availability of generic versions of autoinjectors and advantages offered by autoinjectors in emergency medical care is expected to propel the growth of the market.
Prominent Players
• Becton, Dickinson and Company (BD) (US)
• Ypsomed Holding AG (Switzerland)
• sSHL Medical (Switzerland)
• West Pharmaceutical Services, Inc. (US)
• Recipharm AB (Sweden)
• Haselmeier GmbH (Germany)
• Owen Mumford Ltd. (UK)
• Gerresheimer AG (Germany)
• Phillips-Medisize, LLC (US)
• Oval Medical Technologies Ltd. (UK)
• Kaleo, Inc. (US), Solteam Incorporation Co., Ltd. (China)
• Elcam Drug Delivery Devices (E3D) (Israel)
• Crossject (France)
• Johnson MedTech, LLC. (US), Antares Pharma, Inc. (US)
• Jabil, Inc. (US)
• Congruence Medical Solutions LLC (US)
• AbbVie Inc. (US)
• Amgen Inc. (US)
• Eli Lilly and Company (US)
• Novartis AG (Switzerland)
• Merck KGaA (Germany)
• Viatris Inc. (US)
• Biogen (US)